

## #investmentsciences

## Consumer Staples

# Factors in staples – Q4 update

We update our factor model for 4Q19: Last month we introduced a quantamental, factorbased approach to Global Consumer Staples equity investing in two reports; one providing a thematic overview (A quant approach to Staples selection, 26 Sept 2019) and one setting out formal technical details of our approach (Quantamental factors for Consumer Staples, 26 Sept 2019). Every quarter our model updates, reassessing its highest and lower-scoring quintiles, and also tweaking factor weighting with another period upon which to train. This is the first such quarterly update, using data as of the start of 4Q19.

Five changes to our highest-scoring quintile, four changes to our least: Kobayashi Pharmaceutical, Kose, Reckitt Benckiser, Sundrug and Treasury Wine Estates leave the top quintile. They are replaced by Coles, Dairy Farm, Lawson, Philip Morris and Pola Orbis. Alimentation, Campbell Soup, Casino and Woolworths leave the bottom quintile and are replaced by L'Oréal, NH Foods, Nisshin Seifun and Toyo Suisan. Q3 is not a common period to report annual fundamentals, so these moves have primarily been driven by relative price movements and, to a lesser extent, forecast changes.

Continued outperformance of value in 3Q19 drove slight underperformance: The rotation into value from quality seen in 2Q19 continued into 3Q19, albeit much more gently. This saw our top quintile underperform the index by 81bp, although it outperformed the bottom quintile by 89bp. Our model re-evaluates factor weighting every quarter and modestly increased the importance it places on value factors at the expense of quality. This was a minor change; our model weights factors based on performance from 2008 onwards so the impact of any one quarter is limited.

Investor feedback sets out plenty of areas for further exploration: Since our initial publication on this topic we have had significant investor interest and feedback. For the most part fundamental equity investors have been interested in the importance of Free Cash Flow / Tangible Fixed Assets (TFA) as a metric, and we've had extensive requests for more data here. Our model's relative down-weighting of megacap companies has also been commented on, with some querying whether a linear relationship between market cap and model score is appropriate given how asymmetrically market cap is distributed around the median and mean. Quantitative investors have highlighted that much of systematic quantitative analysis tends to be on a whole-of-market basis, expressing interest in our sector-specific approach. We continue to engage with feedback and look to explore these themes in more detail in due course.

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

This research report has been prepared in whole or in part by equity research analysts based outside the US who are not registered/qualified as research analysts with FINRA. PLEASE SEE ANALYST CERTIFICATION(S) AND IMPORTANT DISCLOSURES BEGINNING ON PAGE 4.

#### **Equity Research**

9 October 2019

#### **INDUSTRY UPDATE**

#### **European Consumer Staples**

**NEUTRAL** 

Unchanged

#### **Investment Sciences**

## North America Food & Staples Retailing

**NEUTRAL** 

Unchanged

## U.S. CHPC & Beverages

**NEUTRAL** 

Unchanged

#### **Investment Sciences**

Ben McSkelly

+44 (0)20 3555 3606

ben.mcskelly@barclays.com

Barclays, UK

#### **European Consumer Staples**

**Iain Simpson** 

+44 (0)20 7773 3616

iain.simpson@barclays.com

Barclays, UK

## **U.S. CHPC & Beverages**

Lauren R. Lieberman

+1 212 526 3112

lauren.lieberman@barclays.com

BCI, US

We update the model detailed in *A quant approach to Staples selection* and *Quantamental factors for Consumer Staples* at the start of the new quarter.

The performance of the two back-testing approaches previously detailed; weighting the full index by score ('score weighted') and selecting the equal weight top 20% of scoring securities ('top quintile') continued to lag in Q3, albeit less than in Q2.

Model continues to lag post quality value rotation in Q2

The score-weighted approach in Q3 lagged the index by 75bps (risk normalised -0.31). This follows the 290bps lag that would have occurred in Q2, as quality-to-value rotation penalised the model's high weighting in Quality. Overall year-to-date cumulative performance for score-weighted is -5%. The top-quintile performance also lagged in Q3, by 81bps, although less than the bottom-quintile underperformance at 170bps.

#### Movers and shakers

Our model now incorporates return information from Q3 as well as updating factor values. The top quintile sees rotation of four five names, with four name changes in the bottom, as shown in Figure 1.

FIGURE 1
Changes in top and bottom-quintile names in Q4 2019

Names exiting top quintile	Kobayashi Pharmaceutical	Kose	Reckitt Benckiser	Sundrug	Treasury Wine Estates
Names entering top quintile	Coles	Dairy Farm Intl	Lawson	Philip Morris	Pola Orbis
Names exiting bottom quintile	Alimentation	Campbell Soup	Casino	Woolworths	
Names entering bottom quintil	e L'Oréal	NH Foods	Nisshin Seifun	Toyo Suisan	

Source: Barclays Research, MSCI, Refinitiv

Q3 is not a common period for annual result announcements, although Campbell Soup, Coles, Treasury Wine Estates and Woolworths Group did release financials in the period, with factor changes across the board. Overall, the main factor driver of these entrants and exits appears to be relative price changes and pass-through effects on valuation and market cap factors. This is particularly telling in Sundrug and Treasury Wine Estates.

Changes in forecast values, particularly our organic growth proxy, were prevalent in Coles, Kobayashi and, to a lesser extent, Sundrug, Nisshin Seifun and Dairy Farm.

## What about factor weight changes?

In addition to the effects of factor value changes, the returns information of a new quarter impacts the weight placed upon each factor. Those factors whose weights increase include (in decreasing order of magnitude) FCF yield, Price to Book, Buyback yield and one-year revenue forecasts. Similarly, factors with decreasing weight include indebtedness, FCF / TFA, proxy organic growth and market value.

Slight rebalance to value due to recent rotation

As one might expect following a quality value rotation, these weight changes represent the model rebalancing slightly to lessen the dominant Quality factor and increase related Value factors. The purpose of this model is to identify how factors influence return over long holding periods, rather than to react strongly to recent market trends.

#### Initial feedback

We welcome feedback on our approach and model...

We intend to incorporate investor feedback into further study and discussion of our model in addition to periodic updates. As one may expect, the most heavily weighted factor, FCF / TFA, has been prominently discussed. In particular, does this represent the ability of strong brands to maximise cash generation from fixed capital investment? Also discussed has been the extent to which this factor helps to separate out M&A related items (intangibles) in cash performance.

Can we do more on market value to move beyond simply penalising megacaps?

The other factors that have sparked discussion are those to which non-linearity appears to be present, notably market value and indebtedness. Penalising companies linearly due to their size has been queried, particularly with otherwise high-quality names in the mega cap portion of the sector. As noted in *A quant approach to Staples selection*, it would appear that whilst moderately small companies outperform, very small companies have a larger underperformance. Additionally, megacaps outperform on average, although with less magnitude. We presented a model that prioritised interpretability for discretionary investors, many of whom have intimated they can parse the limitations of the model in this regard. Nevertheless, we believe investigations of more nuanced approaches to these factors is merited.

Broadly, we noted investors' reactions to the approach of our model, which uses our sector specialists' knowledge to build a model that informs the discretionary narrative. Traditional factor models for security returns can often rely on large training sets across a whole asset class. Restricting factor modelling to a single sector is a less used approach. For a systematic approach, implementing sector-specific knowledge to build and interpret a model at scale, can be difficult. This is a representation of challenges and potential benefits of a quantamental approach. We received interest in applying this approach to other sectors, as well as isolating sub-sector behaviour; how would a similar model behave if only trained on staples retail? We aim not only to update the outputs of our model, but to detail and discuss possible improvements in a transparent way.

FIGURE 2

Top and bottom quintile scoring securities at the beginning of Q4 2019

		5 5 -	
Top-quintile securities	Sub Sector	Bottom-quintile securities	Sub Sector
Altria Group	Tobacco	Aeon	Retail
Barry Callebaut	Food	Anheuser-Busch InBev	Beverages
Brown-Forman 'B'	Beverages	Carrefour	Retail
Church & Dwight Co.	HPC	Coca Cola	Beverages
Clorox	HPC	Conagra Brands	Food
Coca-Cola Bottlers Japan Holdings	Beverages	Costco Wholesale	Retail
Coles Group	Retail	Coty Cl.A	HPC
Colgate-Palm.	HPC	Golden Agri-Resources	Food
Dairy Farm Intl.Hdg.	Food	Heineken	Beverages
Hershey	Food	L'Oreal	HPC
Imperial Brands	Tobacco	Meiji Holdings	Food
Ingredion	Food	Nestle 'R'	Food
Japan Tobacco	Tobacco	Nh Foods	Food
Koninklijke Ahold Delhaize	Retail	Nisshin Seifun	Food
Kroger	Retail	Nissin Foods Holdings	Food
Lawson	Retail	Pepsico	Beverages
Mccormick & Company Nv.	Food	Procter & Gamble	HPC
Monster Beverages	Beverages	Seven & I Hdg.	Retail
Philip Morris Intl.	Tobacco	Tesco	Retail
Pola Orbis Holdings	HPC	Toyo Suisan Kaisha	Food
Swedish Match	Tobacco	Walmart	Retail
Sysco	Retail	Wilmar Intl.	Food
The A2 Milk Company	Food	Yamazaki Baking	Food
Walgreens Boots Alliance	Retail		
Source: Barclays Research, MSCI, Refinitiv			

#### ANALYST(S) CERTIFICATION(S):

We, Ben McSkelly and lain Simpson, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

#### IMPORTANT DISCLOSURES

Barclays Research is produced by the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays"). All authors contributing to this research report are Research Analysts unless otherwise indicated. The publication date at the top of the report reflects the local time where the report was produced and may differ from the release date provided in GMT.

#### Availability of Disclosures:

Where any companies are the subject of this research report, for current important disclosures regarding those companies please refer to https://publicresearch.barclays.com or alternatively send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or call +1-212-526-1072.

The analysts responsible for preparing this research report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by investment banking activities, the profitability and revenues of the Markets business and the potential interest of the firm's investing clients in research with respect to the asset class covered by the analyst.

Research analysts employed outside the US by affiliates of Barclays Capital Inc. are not registered/qualified as research analysts with FINRA. Such non-US research analysts may not be associated persons of Barclays Capital Inc., which is a FINRA member, and therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst's account.

Analysts regularly conduct site visits to view the material operations of covered companies, but Barclays policy prohibits them from accepting payment or reimbursement by any covered company of their travel expenses for such visits.

Barclays Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of Barclays Research may differ from those contained in other types of Barclays Research, whether as a result of differing time horizons, methodologies, or otherwise.

In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to https://publicresearch.barcap.com/S/RD.htm. In order to access Barclays Research Conflict Management Policy Statement, please refer to: https://publicresearch.barcap.com/S/CM.htm.

Materially Mentioned Stocks (Ticker, Date, Price)

Ahold Delhaize (AD.AS, 07-Oct-2019, EUR 22.70), Equal Weight/Neutral, B/CD/J

Alimentation Couche-Tard Inc. (ATD-B.TO, 07-Oct-2019, CAD 40.38), Overweight/Neutral, CD/D/J/K/L/M/N/U

Altria Group Inc. (MO, 07-Oct-2019, USD 42.17), Overweight/Neutral, A/CD/CE/D/J/K/L/M

Anheuser-Busch InBev (ABI.BR, 07-Oct-2019, EUR 85.39), Underweight/Neutral, A/CD/CE/D/J/K/L/M/N

Barry Callebaut (BARN.S, 07-Oct-2019, CHF 2078.00), Overweight/Neutral, J

Brown-Forman (BFb, 07-Oct-2019, USD 62.47), Equal Weight/Neutral, CD/J/K/M/N

Campbell Soup (CPB, 07-Oct-2019, USD 47.00), Underweight/Neutral, CD/CE/D/E/J/K/L/M

Carrefour (CARR.PA, 07-Oct-2019, EUR 15.15), Equal Weight/Neutral, CD/D/FA/J/K/L/M/N

Casino (CASP.PA, 07-Oct-2019, EUR 42.14), Underweight/Neutral, CD/J

Church & Dwight Co., Inc. (CHD, 07-Oct-2019, USD 76.05), Underweight/Neutral, CD/CE/J/K/N

Clorox Company (CLX, 07-Oct-2019, USD 151.16), Underweight/Neutral, CD/CE/J/K/M/N

Colgate-Palmolive (CL, 07-Oct-2019, USD 71.62), Equal Weight/Neutral, A/CD/CE/D/J/K/L/M

Conagra Brands (CAG, 07-Oct-2019, USD 28.63), Overweight/Neutral, A/CD/CE/D/J/K/L/M

Costco Wholesale Corp. (COST, 07-Oct-2019, USD 293.41), Equal Weight/Neutral, CD/CE/D/J/K/L/M/N

Coty Inc. (COTY, 07-Oct-2019, USD 10.34), Equal Weight/Neutral, CD/CE/J/K/M

Heineken NV (HEIN.AS, 07-Oct-2019, EUR 97.42), Overweight/Neutral, CD/D/E/J/K/L/M/N

Imperial Brands Plc (IMB.L, 07-Oct-2019, GBp 1830), Overweight/Neutral, A/D/E/J/K/L/M/N/Q

Japan Tobacco Inc. (JAPAY, 07-Oct-2019, USD 10.95), Underweight/Neutral, CD/J/K/N

Kroger Co. (KR, 07-Oct-2019, USD 24.84), Equal Weight/Neutral, CD/CE/J

L'Oréal SA (OREP.PA, 07-Oct-2019, EUR 248.00), Equal Weight/Neutral, J/K/N

McCormick & Co. (MKC, 07-Oct-2019, USD 168.22), Equal Weight/Neutral, CD/CE/J

Nestle SA (NESN.S, 07-Oct-2019, CHF 107.80), Overweight/Neutral, CD/D/E/J/K/L/M/N

PepsiCo Inc. (PEP, 07-Oct-2019, USD 138.34), Equal Weight/Neutral, A/CD/CE/D/J/K/L/M

Philip Morris International Inc. (PM, 07-Oct-2019, USD 77.17), Overweight/Neutral, A/CD/CE/D/E/J/K/L/M

Procter & Gamble (PG, 07-Oct-2019, USD 122.84), Overweight/Neutral, A/CD/CE/D/E/J/K/L/M

Reckitt Benckiser Group PLC (RB.L, 07-Oct-2019, GBp 6258), Overweight/Neutral, CD/J/K/M/N

Swedish Match (SWMA.ST, 07-Oct-2019, SEK 403.70), Overweight/Neutral, CD/FA/J

SYSCO Corp. (SYY, 07-Oct-2019, USD 78.22), Equal Weight/Neutral, CD/CE/D/J/K/L/M/N

Tesco (TSCO.L, 07-Oct-2019, GBP 2.37), Overweight/Neutral, A/CD/D/E/J/K/L/M/N/Q

The Coca-Cola Company (KO, 07-Oct-2019, USD 53.87), Overweight/Neutral, A/CD/CE/D/J/K/L/M/N

The Hershey Company (HSY, 07-Oct-2019, USD 157.70), Equal Weight/Neutral, CD/CE/J

Walgreens Boots Alliance (WBA, 07-Oct-2019, USD 52.76), Equal Weight/Neutral, CD/CE/J/K/N

Walmart Inc. (WMT, 07-Oct-2019, USD 117.23), Overweight/Neutral, A/CD/CE/D/E/J/K/L/M/N/R

Non-covered Stocks (Ticker, Date, Price)

A2 MILK CO LTD (ATM.NZ, 07-Oct-2019, NZD 13.19, Refinitiv), J

AEON CO LTD (8267.T, 07-Oct-2019, JPY 2008, Refinitiv), A/CD/D/J/K/L/M

COCA-COLA BOTTLERS JAPAN HOL (2579.T, 07-Oct-2019, JPY 2440, Refinitiv), CD/J

COLES GROUP LTD (COL.AX, 07-Oct-2019, AUD 15.06, Refinitiv), J

DAIRY FARM INTL HLDGS LTD (DAIR.SI, 07-Oct-2019, USD 6.13, Refinitiv), J

GOLDEN AGRI-RESOURCES LTD (GAGR.SI, 07-Oct-2019, SGD 0.21, Refinitiv), D/J/K/L/M

INGREDION INC (INGR, 07-Oct-2019, USD 78.34, Refinitiv), CD/J

KOBAYASHI PHARMACEUTICAL CO (4967.T, 07-Oct-2019, JPY 8410, Refinitiv), J

KOSE CORP (4922.T, 07-Oct-2019, JPY 18110, Refinitiv), J

LAWSON INC (2651.T, 07-Oct-2019, JPY 5680, Refinitiv), J

MEIJI HOLDINGS CO LTD (2269.T, 07-Oct-2019, JPY 7680, Refinitiv), CD/J/K/N

MONSTER BEVERAGE CORP (MNST, 07-Oct-2019, USD 55.73, Refinitiv), CE/J

NH FOODS LTD (2282.T, 07-Oct-2019, JPY 4495, Refinitiv), CD/J

NISSHIN SEIFUN GROUP INC (2002.T, 07-Oct-2019, JPY 1967, Refinitiv), CD/J

NISSIN FOODS HOLDINGS CO LTD (2897.T, 07-Oct-2019, JPY 7960, Refinitiv), J

POLA ORBIS HOLDINGS INC (4927.T, 07-Oct-2019, JPY 2383, Refinitiv), J

SEVEN & I HOLDINGS CO LTD (3382.T, 07-Oct-2019, JPY 4119, Refinitiv), CD/J

SUNDRUG CO LTD (9989.T, 07-Oct-2019, JPY 3425, Refinitiv), J

TOYO SUISAN KAISHA LTD (2875.T, 07-Oct-2019, JPY 4275, Refinitiv), J

TREASURY WINE ESTATES LTD (TWE.AX, 07-Oct-2019, AUD 18.16, Refinitiv), J

WILMAR INTERNATIONAL LTD (WLIL.SI, 07-Oct-2019, SGD 3.63, Refinitiv), CD/D/J/K/L/M

WOOLWORTHS GROUP LTD (WOW.AX, 07-Oct-2019, AUD 36.81, Refinitiv), CD/J

YAMAZAKI BAKING CO LTD (2212.T, 07-Oct-2019, JPY 1943, Refinitiv), J

Unless otherwise indicated, prices are sourced from Refinitiv and reflect the closing price in the relevant trading market, which may not be the last available price at the time of publication.

#### **Disclosure Legend:**

A: Barclays Bank PLC and/or an affiliate has been lead manager or co-lead manager of a publicly disclosed offer of securities of the issuer in the previous 12 months.

**B**: An employee or non-executive director of Barclays PLC is a director of this issuer.

CD: Barclays Bank PLC and/or an affiliate is a market-maker in debt securities issued by this issuer.

CE: Barclays Bank PLC and/or an affiliate is a market-maker in equity securities issued by this issuer.

D: Barclays Bank PLC and/or an affiliate has received compensation for investment banking services from this issuer in the past 12 months.

E: Barclays Bank PLC and/or an affiliate expects to receive or intends to seek compensation for investment banking services from this issuer within the next 3 months.

FA: Barclays Bank PLC and/or an affiliate beneficially owns 1% or more of a class of equity securities of this issuer, as calculated in accordance with US regulations.

FB: Barclays Bank PLC and/or an affiliate beneficially owns a long position of more than 0.5% of a class of equity securities of this issuer, as calculated in accordance with EU regulations.

9 October 2019 5

FC: Barclays Bank PLC and/or an affiliate beneficially owns a short position of more than 0.5% of a class of equity securities of this issuer, as calculated in accordance with EU regulations.

GD: One of the analysts on the fundamental credit coverage team (or a member of his or her household) has a financial interest in the debt or equity securities of this issuer.

GE: One of the analysts on the fundamental equity coverage team (or a member of his or her household) has a financial interest in the debt or equity securities of this issuer.

H: This issuer beneficially owns more than 5% of any class of common equity securities of Barclays PLC.

I: Barclays Bank PLC and/or an affiliate is party to an agreement with this issuer for the provision of financial services to Barclays Bank PLC and/or an affiliate

J: Barclays Bank PLC and/or an affiliate is a liquidity provider and/or trades regularly in the securities of this issuer and/or in any related derivatives.

K: Barclays Bank PLC and/or an affiliate has received non-investment banking related compensation (including compensation for brokerage services, if applicable) from this issuer within the past 12 months.

L: This issuer is, or during the past 12 months has been, an investment banking client of Barclays Bank PLC and/or an affiliate.

M: This issuer is, or during the past 12 months has been, a non-investment banking client (securities related services) of Barclays Bank PLC and/or an affiliate.

N: This issuer is, or during the past 12 months has been, a non-investment banking client (non-securities related services) of Barclays Bank PLC and/or an affiliate.

O: Not in use.

P: A partner, director or officer of Barclays Capital Canada Inc. has, during the preceding 12 months, provided services to the subject company for remuneration, other than normal course investment advisory or trade execution services.

Q: Barclays Bank PLC and/or an affiliate is a Corporate Broker to this issuer.

R: Barclays Capital Canada Inc. and/or an affiliate has received compensation for investment banking services from this issuer in the past 12 months.

S: This issuer is a Corporate Broker to Barclays PLC.

T: Barclays Bank PLC and/or an affiliate is providing equity advisory services to this issuer.

U: The equity securities of this Canadian issuer include subordinate voting restricted shares.

V: The equity securities of this Canadian issuer include non-voting restricted shares.

#### Risk Disclosure(s)

Master limited partnerships (MLPs) are pass-through entities structured as publicly listed partnerships. For tax purposes, distributions to MLP unit holders may be treated as a return of principal. Investors should consult their own tax advisors before investing in MLP units.

The MSCI sourced information is the exclusive property of MSCI Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI and the MSCI indexes are services marks of MSCI and its affiliates.

#### Guide to the Barclays Fundamental Equity Research Rating System:

Our coverage analysts use a relative rating system in which they rate stocks as Overweight, Equal Weight or Underweight (see definitions below) relative to other companies covered by the analyst or a team of analysts that are deemed to be in the same industry (the "industry coverage universe").

In addition to the stock rating, we provide industry views which rate the outlook for the industry coverage universe as Positive, Neutral or Negative (see definitions below). A rating system using terms such as buy, hold and sell is not the equivalent of our rating system. Investors should carefully read the entire research report including the definitions of all ratings and not infer its contents from ratings alone.

### Stock Rating

**Overweight** - The stock is expected to outperform the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

Equal Weight - The stock is expected to perform in line with the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

**Underweight** - The stock is expected to underperform the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

Rating Suspended - The rating and target price have been suspended temporarily due to market events that made coverage impracticable or to comply with applicable regulations and/or firm policies in certain circumstances including where the Investment Bank of Barclays Bank PLC is acting in an advisory capacity in a merger or strategic transaction involving the company.

9 October 2019 6

#### **Industry View**

Positive - industry coverage universe fundamentals/valuations are improving.

Neutral - industry coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.

DIA (DIDA.MC)

Metro AG (B4B.DE)

Brown-Forman (BFb)

Campbell Soup (CPB)

Rallye (GENC.PA)

Tesco (TSCO.L)

**Negative** - industry coverage universe fundamentals/valuations are deteriorating.

Below is the list of companies that constitute the "industry coverage universe":

Euro	pean	Consumer	Stap	les

A.G. Barr PLC (BAG.L)	Altria Group Inc. (MO)	Anheuser-Busch InBev (ABI.BR)
Associated British Foods (ABF.L)	Bakkavor (BAKK.L)	Barry Callebaut (BARN.S)
Beiersdorf AG (BEIG.DE)	British American Tobacco Plc (BATS.L)	Britvic PLC (BVIC.L)
Carlsberg AS-B (CARLb.CO)	Chr. Hansen Holding A/S (CHRH.CO)	Coca-Cola Hellenic BC AG (CCH.L)
Danone (DANO.PA)	Davide Campari-Milano SpA (CPRI.MI)	Diageo PLC (DGE.L)
Essity (ESSITYb.ST)	Glanbia PLC (GL9.I)	Greencore Group PLC (GNC.L)
Heineken NV (HEIN.AS)	Henkel (HNKG_p.DE)	Imperial Brands Plc (IMB.L)
Japan Tobacco Inc. (JAPAY)	Kerry Group PLC (KYGa.L)	L'Oréal SA (OREP.PA)
Lindt & Spruengli (LISN.S)	Nestle SA (NESN.S)	Ontex Group (ONTEX.BR)
Pernod-Ricard SA (PERP.PA)	Philip Morris International Inc. (PM)	Reckitt Benckiser Group PLC (RB.L)
Rémy Cointreau (RCOP.PA)	Swedish Match (SWMA.ST)	Tate & Lyle PLC (TATE.L)
Unilever NV (UNA.AS)	Unilever PLC (ULVR.L)	
European Food Retail		
Ahold Delhaize (AD.AS)	Carrefour (CARR.PA)	Casino (CASP.PA)

## Sonae (YSO.LS) North America Food & Staples Retailing

Alimentation Couche-Tard Inc. (ATD-B.TO)	Big Lots, Inc. (BIG)	BJ's Wholesale Club Holdings, Inc. (BJ)
Casey's General Stores Inc (CASY)	Costco Wholesale Corp. (COST)	Dollar General Corporation (DG)
Dollar Tree Inc (DLTR)	Dollarama Inc. (DOL.TO)	Empire Co., Ltd. (EMP-A.TO)
Five Below, Inc. (FIVE)	Grocery Outlet Holding Corp (GO)	Kroger Co. (KR)
Loblaw Cos., Ltd. (L.TO)	Metro Inc. (MRU.TO)	SpartanNash Co (SPTN)
Sprouts Farmers Market Inc (SFM)	Target Corp. (TGT)	United Natural Foods, Inc. (UNFI)
Walmart Inc. (WMT)		

ICA GRUPPEN AB (ICAA.ST)

Sainsbury (J) plc (SBRY.L)

Church & Dwight Co., Inc. (CHD)

Conagra Brands (CAG)

Morrison (MRW.L)

## U.S. CHPC & Beverages Avon Products (AVP)

Colruyt (COLR.BR)

Ocado (OCDO.L)

Jeronimo Martins (JMT.LS)

U.S. Food		
Sundial Growers, Inc. (SNDL)	The Coca-Cola Company (KO)	The Estée Lauder Companies (EL)
Newell Brands Inc. (NWL)	PepsiCo Inc. (PEP)	Procter & Gamble (PG)
Keurig Dr Pepper (KDP)	Kimberly-Clark Corp. (KMB)	Molson Coors Brewing Company (TAP)
Edgewell Personal Care Company (EPC)	Energizer Holdings, Inc (ENR)	International Flavors & Fragrances (IFF)
Colgate-Palmolive (CL)	Constellation Brands (STZ)	Coty Inc. (COTY)
Clorox Company (CLX)	Coca-Cola European Partners PLC (CCE.AS)	Coca-Cola European Partners PLC (CCEP)

B&G Foods (BGS)

General Mills (GIS)	Hain Celestial (HAIN)	Kellogg Co. (K)
Lamb Weston Holdings, Inc. (LW)	McCormick & Co. (MKC)	Mondelez International (MDLZ)
Nomad Foods Ltd. (NOMD)	Post Holdings, Inc. (POST)	The Hershey Company (HSY)
The J.M. Smucker Company (SJM)	The Kraft Heinz Company (KHC)	TreeHouse Foods (THS)

### **U.S. Health Care Services**

Align Technology (ALGN)	Amedisys, Inc. (AMED)	American Renal Associates Holdings Inc. (ARA)
AmerisourceBergen Corp. (ABC)	Anthem (ANTM)	Brookdale Senior Living Inc. (BKD)
Capital Senior Living Corporation (CSU)	Cardinal Health (CAH)	CareTrust REIT, Inc. (CTRE)
Centene (CNC)	Cerner (CERN)	Cigna (CI)
Community Health Systems Inc. (CYH)	CVS Health (CVS)	DaVita Inc. (DVA)
Dentsply Sirona (XRAY)	Diplomat Pharmacy Inc. (DPLO)	Encompass Health Corp. (EHC)
HCA Healthcare, Inc. (HCA)	HCP, Inc. (HCP)	Henry Schein (HSIC)
Humana (HUM)	LHC Group, Inc. (LHCG)	McKesson (MCK)
Medical Properties Trust Inc. (MPW)	Molina Healthcare (MOH)	Owens & Minor (OMI)
Patterson Companies (PDCO)	Premier Inc. (PINC)	Sabra Health Care REIT, Inc. (SBRA)
Select Medical Holdings Corporation (SEM)	Tenet Healthcare Inc. (THC)	UnitedHealth Group (UNH)
Universal Health Services Inc. (UHS)	Ventas, Inc. (VTR)	Walgreens Boots Alliance (WBA)
WellCare Health Plans (WCG)	Welltower, Inc. (WELL)	
U.S. Restaurants		
BJ's Restaurants Inc (BJRI)	Bloomin' Brands, Inc. (BLMN)	Brinker International (EAT)
Chipotle Mexican Grill, Inc. (CMG)	Darden Restaurants (DRI)	Dine Brands Global (DIN)
Domino's Pizza (DPZ)	Dunkin' Brands Group (DNKN)	Jack in the Box Inc. (JACK)
McDonald's Corp. (MCD)	Performance Food Group Co. (PFGC)	Restaurant Brands International (QSR)
Shake Shack Inc. (SHAK)	Starbucks Corp. (SBUX)	SYSCO Corp. (SYY)
Texas Roadhouse, Inc. (TXRH)	The Cheesecake Factory (CAKE)	The Wendy's Company (WEN)
US Foods Holdings Corp (USFD)	Wingstop Inc. (WING)	Yum! Brands Inc. (YUM)

#### **Distribution of Ratings:**

Barclays Equity Research has 1560 companies under coverage.

44% have been assigned an Overweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Buy rating; 55% of companies with this rating are investment banking clients of the Firm; 75% of the issuers with this rating have received financial services from the Firm.

39% have been assigned an Equal Weight rating which, for purposes of mandatory regulatory disclosures, is classified as a Hold rating; 50% of companies with this rating are investment banking clients of the Firm; 69% of the issuers with this rating have received financial services from the Firm.

15% have been assigned an Underweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Sell rating; 34% of companies with this rating are investment banking clients of the Firm; 66% of the issuers with this rating have received financial services from the Firm.

#### Guide to the Barclays Research Price Target:

Each analyst has a single price target on the stocks that they cover. The price target represents that analyst's expectation of where the stock will trade in the next 12 months. Upside/downside scenarios, where provided, represent potential upside/potential downside to each analyst's price target over the same 12-month period.

#### Top Picks:

Barclays Equity Research's "Top Picks" represent the single best alpha-generating investment idea within each industry (as defined by the relevant "industry coverage universe"), taken from among the Overweight-rated stocks within that industry. Barclays Equity Research publishes "Top Picks" reports every quarter and analysts may also publish intra-quarter changes to their Top Picks, as necessary. While analysts may highlight other Overweight-rated stocks in their published research in addition to their Top Pick, there can only be one "Top Pick" for each industry. To view the current list of Top Picks, go to the Top Picks page on Barclays Live (https://live.barcap.com/go/keyword/TopPicks).

To see a list of companies that comprise a particular industry coverage universe, please go to https://publicresearch.barclays.com.

#### Types of investment recommendations produced by Barclays Equity Research:

In addition to any ratings assigned under Barclays' formal rating systems, this publication may contain investment recommendations in the form of trade ideas, thematic screens, scorecards or portfolio recommendations that have been produced by analysts within Equity Research. Any such investment recommendations shall remain open until they are subsequently amended, rebalanced or closed in a future research report.

#### Disclosure of other investment recommendations produced by Barclays Equity Research:

Barclays Equity Research may have published other investment recommendations in respect of the same securities/instruments recommended in this research report during the preceding 12 months. To view all investment recommendations published by Barclays Equity Research in the preceding 12 months please refer to <a href="https://live.barcap.com/go/research/Recommendations">https://live.barcap.com/go/research/Recommendations</a>.

9 October 2019 8

Legal entities involved in producing Barclays Research:

Barclays Bank PLC (Barclays, UK)

Barclays Capital Inc. (BCI, US)

Barclays Bank Ireland PLC, Frankfurt Branch (BBI, Frankfurt)

Barclays Bank Ireland PLC, Paris Branch (BBI, Paris)

Barclays Bank Ireland PLC, Milan Branch (BBI, Milan)

Barclays Securities Japan Limited (BSJL, Japan)

Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)

Barclays Capital Canada Inc. (BCCI, Canada)

Barclays Bank Mexico, S.A. (BBMX, Mexico)

Barclays Securities (India) Private Limited (BSIPL, India)

Barclays Bank PLC, India branch (Barclays Bank, India)

Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)

#### DISCLAIMER:

This publication has been produced by Barclays Research Department in the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been prepared for institutional investors only and not for retail investors. It has been distributed by one or more Barclays affiliated legal entities listed below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. To the extent that this publication states on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an "institutional debt research report" and distribution to retail investors is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, media, regulatory and academic organisations for their own internal informational news gathering, regulatory or academic purposes and not for the purpose of making investment decisions regarding any debt securities. Media organisations are prohibited from re-publishing any opinion or recommendation concerning a debt issuer or debt security contained in any Barclays institutional debt research report. Any such recipients that do not want to continue receiving Barclays institutional debt research parclays.com. Barclays will not treat unauthorized recipients of this report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the information or opinions contained in any written, electronic, audio or video presentations of third parties that are accessible via a direct hyperlink in this publication or via a hyperlink to a third-party web site ('Third-Party Content'). Any such Third-Party Content has not been adopted or endorsed by Barclays, does not represent the views or opinions of Barclays, and is not incorporated by reference into this publication. Third-Party Content is provided for information purposes only and Barclays has not independently verified its accuracy or completeness.

The views in this publication are solely and exclusively those of the authoring analyst(s) and are subject to change, and Barclays Research has no obligation to update its opinions or the information in this publication. Unless otherwise disclosed herein, the analysts who authored this report have not received any compensation from the subject companies in the past 12 months. If this publication contains recommendations, they are general recommendations that were prepared independently of any other interests, including those of Barclays and/or its affiliates, and/or the subject companies. This publication does not contain personal investment recommendations or investment advice or take into account the individual financial circumstances or investment objectives of the clients who receive it. The securities and other investments discussed herein may not be suitable for all investors. Barclays is not a fiduciary to any recipient of this publication. Investors must independently evaluate the merits and risks of the investments discussed herein, consult any independent advisors they believe necessary, and exercise independent judgment with regard to any investment decision. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results. The information provided does not constitute a financial benchmark and should not be used as a submission or contribution of input data for the purposes of determining a financial benchmark.

United Kingdom: This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons in the United Kingdom having professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom it may otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity to which this communication relates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

**European Economic Area ("EEA"):** This material is being distributed in the EEA by Barclays Bank PLC. Barclays Bank PLC is not registered in France with the Autorité des marchés financiers or the Autorité de contrôle prudentiel.

Americas: The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC (www.iiroc.ca), and a Member of the Canadian Investor Protection Fund (CIPF).

This material is distributed in Mexico by Barclays Bank Mexico, S.A.

Japan: This material is being distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokucho (kinsho) No. 143.

Asia Pacific (excluding Japan): Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

All Indian securities-related research and other equity research produced by Barclays' Investment Bank are distributed in India by Barclays Securities (India) Private Limited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered and regulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585; Stock Broker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & Options INF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & Options INF011292738; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli, Mumbai – 400 018, India. Telephone No: +91 2267196000. Fax number: +91 22 67196100. Any other reports produced by Barclays' Investment Bank are distributed in India by Barclays Bank PLC, India Branch, an associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a Banking Company under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn No INM000002129) and also as Banker to the Issue (Regn No INB100000950). Barclays Investments and Loans (India) Limited, registered with RBI as Non Banking Financial Company (Regn No RBI CoR-07-00258), and Barclays Wealth Trustees (India) Private Limited, registered with Registrar of Companies (CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by Barclays' Investment Bank.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this material, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10 Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.

This material is distributed to persons in Australia by Barclays Bank PLC. None of Barclays Bank PLC, nor any other Barclays group entity, holds an Australian financial services licence and instead relies on an exemption from the requirement to hold such a licence. This material is intended to only be distributed to "wholesale clients" as defined by the Australian Corporations Act 2001.

Middle East: Nothing herein should be considered investment advice as defined in the Israeli Regulation of Investment Advisory, Investment Marketing and Portfolio Management Law, 1995 ("Advisory Law"). This document is being made to eligible clients (as defined under the Advisory Law) only. Barclays Israeli branch previously held an investment marketing license with the Israel Securities Authority but it cancelled such license on 30/11/2014 as it solely provides its services to eligible clients pursuant to available exemptions under the Advisory Law, therefore a license with the Israel Securities Authority is not required. Accordingly, Barclays does not maintain an insurance coverage pursuant to the Advisory Law.

This material is distributed in the United Arab Emirates (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC. Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority. Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi). Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

Russia: This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain information about or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus not eligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of this material in your possession.

IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2019). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.